ALXN 5500

Drug Profile

ALXN 5500

Alternative Names: ALXN5500

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Immunological disorders

Most Recent Events

  • 01 Jul 2014 Phase-I clinical trials in Immunological disorders in USA (unspecified route)
  • 01 Jan 2013 Alexion Pharmaceuticals enters into an option and technology license agreement with Xencor for the development of ALXN 5500 (Xencor 2013 Form 10-K; 9160766)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top